154 related articles for article (PubMed ID: 18680235)
1. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.
Feng GS; Ma JL; Wong BC; Zhang L; Liu WD; Pan KF; Shen L; Zhang XD; Li J; Xia HH; Li JY; Lam SK; You WC
World J Gastroenterol; 2008 Jul; 14(28):4535-9. PubMed ID: 18680235
[TBL] [Abstract][Full Text] [Related]
2. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Arber N; Lieberman D; Wang TC; Zhang R; Sands GH; Bertagnolli MM; Hawk ET; Eagle C; Coindreau J; Zauber A; Lanas A; Levin B
Clin Ther; 2012 Mar; 34(3):569-79. PubMed ID: 22386831
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
[TBL] [Abstract][Full Text] [Related]
4. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
Cheung R; Cheng TT; Dong Y; Lin HY; Lai K; Lau CS; Feng H; Parsons B
Int J Rheum Dis; 2010 May; 13(2):151-7. PubMed ID: 20536600
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Huang WF; Hsiao FY; Tsai YW; Wen YW; Shih YT
Drug Saf; 2006; 29(3):261-72. PubMed ID: 16524325
[TBL] [Abstract][Full Text] [Related]
7. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study.
Sakamoto C; Kawai T; Nakamura S; Sugioka T; Tabira J
Aliment Pharmacol Ther; 2013 Feb; 37(3):346-54. PubMed ID: 23216412
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
10. Chemopreventive effect of celecoxib in gastric cancer.
Futagami S; Suzuki K; Hiratsuka T; Shindo T; Hamamoto T; Ueki N; Kusunoki M; Miyake K; Gudis K; Tsukui T; Sakamoto C
Inflammopharmacology; 2007 Feb; 15(1):1-4. PubMed ID: 17323186
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
12. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.
Wong BC; Zhang L; Ma JL; Pan KF; Li JY; Shen L; Liu WD; Feng GS; Zhang XD; Li J; Lu AP; Xia HH; Lam S; You WC
Gut; 2012 Jun; 61(6):812-8. PubMed ID: 21917649
[TBL] [Abstract][Full Text] [Related]
13. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Breazna A; Kim K; Tang J; Rosenstein RB; Umar A; Bagheri D; Collins NT; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Hawk ET;
Cancer Prev Res (Phila); 2009 Apr; 2(4):310-21. PubMed ID: 19336730
[TBL] [Abstract][Full Text] [Related]
14. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
[TBL] [Abstract][Full Text] [Related]
15. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
Wittenberg RH; Schell E; Krehan G; Maeumbaed R; Runge H; Schlüter P; Fashola TO; Thurston HJ; Burger KJ; Trechsel U
Arthritis Res Ther; 2006; 8(2):R35. PubMed ID: 16469112
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.
Moberly JB; Xu J; Desjardins PJ; Daniels SE; Bandy DP; Lawson JE; Link AJ; Truitt KE
Clin Ther; 2007 Mar; 29(3):399-412. PubMed ID: 17577461
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
18. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Elmets CA; Viner JL; Pentland AP; Cantrell W; Lin HY; Bailey H; Kang S; Linden KG; Heffernan M; Duvic M; Richmond E; Elewski BE; Umar A; Bell W; Gordon GB
J Natl Cancer Inst; 2010 Dec; 102(24):1835-44. PubMed ID: 21115882
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Chan FK; Hung LC; Suen BY; Wong VW; Hui AJ; Wu JC; Leung WK; Lee YT; To KF; Chung SC; Sung JJ
Gastroenterology; 2004 Oct; 127(4):1038-43. PubMed ID: 15480981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]